MediWound Q4 Revenue $1.867M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MDWD?
Reports Q4 revenue $1.867M, consensus $2.09M. "We entered 2026 with two strategic growth drivers," said Ofer Gonen, Chief Executive Officer of MediWound. "Our Phase III VALUE trial of EscharEx continues to progress as planned, with key clinical milestones, including interim assessment and enrollment completion, anticipated by year-end. In parallel, our expanded NexoBrid manufacturing facility is now operational, positioning us to support global demand following regulatory approvals. With these value-creating catalysts, a strong balance sheet, and an experienced team, MediWound is now well-positioned to advance into a new phase of scale and commercial readiness."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDWD
Wall Street analysts forecast MDWD stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.490
Low
25.00
Averages
30.00
High
36.00
Current: 17.490
Low
25.00
Averages
30.00
High
36.00
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MediWound Ltd. Q4 2025 Earnings Call Insights
- Revenue Decline: Q4 2025 revenue was $1.9 million, down significantly from $5.8 million in Q4 2024, primarily due to reduced development services revenue linked to the U.S. government shutdown, highlighting financial pressures during critical periods.
- Increased R&D Spending: R&D expenses rose from $3 million to $4.5 million, indicating ongoing investment in the EscharEx Phase III clinical trial, which, while increasing short-term financial burdens, lays the groundwork for future product launches.
- Manufacturing Capacity Expansion: The operational launch of the expanded NexoBrid facility increases production capacity sixfold, with regulatory approvals for commercial output expected in 2026, providing robust support for long-term growth in the trauma care market.
- Future Outlook: Management reaffirmed revenue guidance of $24 million to $26 million for 2026, and despite risks associated with reliance on government contracts, the company remains focused on clinical milestones and commercial objectives, demonstrating confidence in future growth.
See More
MediWound Files Annual Report for FY2025
- Annual Report Filing: MediWound Ltd. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on March 5, 2026, reflecting the company's commitment to compliance and transparency to bolster investor confidence.
- Financial Information Access: The annual report is accessible via the SEC's website and the company's investor relations site, demonstrating MediWound's emphasis on information disclosure to enhance shareholders' understanding of its financial health.
- Shareholder Services: The company offers free hard copies of the annual report upon request, showcasing its dedication to shareholder interests and service commitments, which can strengthen shareholder relations.
- Product Pipeline Update: MediWound's FDA-approved product NexoBrid® and investigational therapy EscharEx® highlight the company's innovative capabilities in tissue repair, potentially driving future market growth.
See More
MediWound Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Highlight: MediWound reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.07, indicating some improvement in financial management despite overall poor performance.
- Revenue Decline: The company's Q4 revenue of $1.87 million represents a 68% year-over-year decline, missing expectations, which reflects weak market demand and sales challenges that could impact future investor confidence.
- Future Guidance: MediWound reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028, demonstrating confidence in future growth, particularly relying on support from BARDA and the U.S. Department of War.
- Product Potential: The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval, which could provide new growth momentum for the company and enhance market expectations regarding its long-term value.
See More
MediWound to Announce Q4 Earnings on March 5
- Earnings Announcement Date: MediWound (MDWD) is set to announce its Q4 2023 earnings on March 5 before market open, with a consensus EPS estimate of -$0.61, reflecting a significant 69.4% year-over-year decline, indicating substantial profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $2.09 million, down 64.2% year-over-year, highlighting the company's struggles with market competition and product demand, which could impact future liquidity and investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, indicating considerable performance volatility that may lead to cautious investor sentiment regarding future results.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced no upward revisions and four downward revisions, suggesting a generally pessimistic outlook from analysts on the company's future performance, which could affect stock price movements.
See More
MediWound Reports NexoBrid Reduces Traumatic Tattoo Risk by 92.5%
- Clinical Data Release: MediWound's new clinical data published in the Journal of Burn Care & Research shows that NexoBrid® effectively prevents traumatic tattoos by significantly reducing embedded particles within 24 hours, achieving over a 90% reduction in pigmented wound area, which opens new possibilities for acute trauma treatment.
- Significant Treatment Effects: In a study involving 15 patients, the application of NexoBrid® reduced the pigmented wound area from 37.5% to 2.1%, with an average of 96% visible pigment removal in friction injuries and 84% in blast injuries, demonstrating its potential in managing complex trauma cases.
- High Safety Profile: The treatment process with NexoBrid® was performed at the bedside, well-tolerated by patients, and no treatment-related adverse events were reported during the early post-procedure period, establishing a solid foundation for its clinical application.
- Future Research Directions: Investigators call for larger controlled studies to confirm the long-term cosmetic effects of NexoBrid® and to explore its combined applications in complex trauma, further advancing the clinical use of this therapy.
See More
MediWound Reports NexoBrid's 92.5% Effectiveness in Preventing Traumatic Tattoos
- Clinical Data Release: MediWound's newly published prospective clinical data demonstrates that NexoBrid effectively prevents traumatic tattoos, with pigmented wound area decreasing from 37.5% to 2.1%, achieving a remarkable 92.5% reduction, significantly enhancing trauma management outcomes.
- Innovative Treatment Method: In a study involving 15 patients, NexoBrid was applied within 24 hours post-injury, successfully removing 96% of visible pigments, indicating its high efficacy in addressing friction and blast injuries, which could potentially transform current trauma care standards.
- Research Context: Conducted at Sheba National Burn Center, this study is the first to evaluate NexoBrid's application in preventing traumatic tattoos, highlighting its selective enzymatic action on damaged skin layers, which holds significant clinical implications.
- Future Research Directions: Despite the small sample size and short follow-up, the investigators call for larger controlled studies to confirm NexoBrid's impact on long-term cosmetic outcomes and to further explore its potential in complex trauma applications.
See More
MediWound Ltd. Q4 2025 Earnings Call Insights
- Revenue Decline: Q4 2025 revenue was $1.9 million, down significantly from $5.8 million in Q4 2024, primarily due to reduced development services revenue linked to the U.S. government shutdown, highlighting financial pressures during critical periods.
- Increased R&D Spending: R&D expenses rose from $3 million to $4.5 million, indicating ongoing investment in the EscharEx Phase III clinical trial, which, while increasing short-term financial burdens, lays the groundwork for future product launches.
- Manufacturing Capacity Expansion: The operational launch of the expanded NexoBrid facility increases production capacity sixfold, with regulatory approvals for commercial output expected in 2026, providing robust support for long-term growth in the trauma care market.
- Future Outlook: Management reaffirmed revenue guidance of $24 million to $26 million for 2026, and despite risks associated with reliance on government contracts, the company remains focused on clinical milestones and commercial objectives, demonstrating confidence in future growth.
See More
MediWound Files Annual Report for FY2025
- Annual Report Filing: MediWound Ltd. filed its Form 20-F annual report for the fiscal year ending December 31, 2025, with the SEC on March 5, 2026, reflecting the company's commitment to compliance and transparency to bolster investor confidence.
- Financial Information Access: The annual report is accessible via the SEC's website and the company's investor relations site, demonstrating MediWound's emphasis on information disclosure to enhance shareholders' understanding of its financial health.
- Shareholder Services: The company offers free hard copies of the annual report upon request, showcasing its dedication to shareholder interests and service commitments, which can strengthen shareholder relations.
- Product Pipeline Update: MediWound's FDA-approved product NexoBrid® and investigational therapy EscharEx® highlight the company's innovative capabilities in tissue repair, potentially driving future market growth.
See More
MediWound Q4 Earnings Beat Expectations Despite Revenue Decline
- Earnings Highlight: MediWound reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.07, indicating some improvement in financial management despite overall poor performance.
- Revenue Decline: The company's Q4 revenue of $1.87 million represents a 68% year-over-year decline, missing expectations, which reflects weak market demand and sales challenges that could impact future investor confidence.
- Future Guidance: MediWound reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028, demonstrating confidence in future growth, particularly relying on support from BARDA and the U.S. Department of War.
- Product Potential: The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval, which could provide new growth momentum for the company and enhance market expectations regarding its long-term value.
See More
MediWound to Announce Q4 Earnings on March 5
- Earnings Announcement Date: MediWound (MDWD) is set to announce its Q4 2023 earnings on March 5 before market open, with a consensus EPS estimate of -$0.61, reflecting a significant 69.4% year-over-year decline, indicating substantial profitability challenges for the company.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $2.09 million, down 64.2% year-over-year, highlighting the company's struggles with market competition and product demand, which could impact future liquidity and investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only beaten EPS estimates 38% of the time and revenue estimates 63% of the time, indicating considerable performance volatility that may lead to cautious investor sentiment regarding future results.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have experienced no upward revisions and four downward revisions, suggesting a generally pessimistic outlook from analysts on the company's future performance, which could affect stock price movements.
See More
MediWound Reports NexoBrid Reduces Traumatic Tattoo Risk by 92.5%
- Clinical Data Release: MediWound's new clinical data published in the Journal of Burn Care & Research shows that NexoBrid® effectively prevents traumatic tattoos by significantly reducing embedded particles within 24 hours, achieving over a 90% reduction in pigmented wound area, which opens new possibilities for acute trauma treatment.
- Significant Treatment Effects: In a study involving 15 patients, the application of NexoBrid® reduced the pigmented wound area from 37.5% to 2.1%, with an average of 96% visible pigment removal in friction injuries and 84% in blast injuries, demonstrating its potential in managing complex trauma cases.
- High Safety Profile: The treatment process with NexoBrid® was performed at the bedside, well-tolerated by patients, and no treatment-related adverse events were reported during the early post-procedure period, establishing a solid foundation for its clinical application.
- Future Research Directions: Investigators call for larger controlled studies to confirm the long-term cosmetic effects of NexoBrid® and to explore its combined applications in complex trauma, further advancing the clinical use of this therapy.
See More
MediWound Reports NexoBrid's 92.5% Effectiveness in Preventing Traumatic Tattoos
- Clinical Data Release: MediWound's newly published prospective clinical data demonstrates that NexoBrid effectively prevents traumatic tattoos, with pigmented wound area decreasing from 37.5% to 2.1%, achieving a remarkable 92.5% reduction, significantly enhancing trauma management outcomes.
- Innovative Treatment Method: In a study involving 15 patients, NexoBrid was applied within 24 hours post-injury, successfully removing 96% of visible pigments, indicating its high efficacy in addressing friction and blast injuries, which could potentially transform current trauma care standards.
- Research Context: Conducted at Sheba National Burn Center, this study is the first to evaluate NexoBrid's application in preventing traumatic tattoos, highlighting its selective enzymatic action on damaged skin layers, which holds significant clinical implications.
- Future Research Directions: Despite the small sample size and short follow-up, the investigators call for larger controlled studies to confirm NexoBrid's impact on long-term cosmetic outcomes and to further explore its potential in complex trauma applications.
See More
